Myrcene (β-Myrcene)

Myrcene – more precisely β-myrcene – is the most abundant terpene in many cannabis cultivars. It smells earthy, musky, of ripe mango and clove, and gives hops their base note in beer. More interesting than the smell is how this small molecule might act in the body. This article summarises the preclinical state of research – hedged, sourced, and without health claims.

Quick facts

  • Class: monoterpene
  • Formula: C₁₀H₁₆ (molar mass 136.23 g/mol)
  • CAS: 123-35-3
  • Isomerism: in nature almost only β-myrcene occurs; the isomer α-myrcene is essentially non-natural and pharmacologically irrelevant. “Myrcene” almost always means β-myrcene.
  • Found in: hops (highest content), mango, lemongrass, thyme, bay, verbena – reviews cite over 200 plants.
  • Do not confuse with: myrcenol (an alcohol) or farnesol (a sesquiterpene alcohol) – different molecules.

β-Myrcene is chemically identical whether taken from the plant or produced industrially from β-pinene.

How myrcene may work

The mechanisms below come mostly from cell-culture and animal studies. Controlled human studies on isolated myrcene are lacking, so all statements are preliminary.

1. The GABA system – the possible calming route

GABA is the brain’s main inhibitory messenger – the “brake”. Several animal studies suggest myrcene may strengthen this brake. In mice, myrcene (100–200 mg/kg) prolonged barbiturate sleep time and reduced locomotion (do Vale et al. 2002). A newer insomnia-model study found β-myrcene raises GABA and serotonin and upregulates the same receptor targets as the sedative diazepam (Chen et al. 2024).

Important caveat: the calming effect appeared only at high doses – and at those doses do Vale et al. even noted a slightly anxiogenic (anxiety-promoting) tinge. Whether the effect truly runs benzodiazepine-like through the GABA-A site is not directly proven for myrcene; it is inferred from related terpenes.

2. Pain relief via the opioid and adrenoceptor systems

Myrcene’s pain-dampening effect in animals seems to take an unusual route. In the classic study by Rao et al. (1990) the effect was abolished by both naloxone (opioid blocker) and yohimbine (α2-adrenoceptor blocker) – suggesting myrcene may trigger the release of the body’s own opioids via α2-adrenoceptors. Lorenzetti et al. (1991) showed peripheral pain inhibition via the prostaglandin (PGE₂) pathway – and, unlike morphine, no tolerance over five days.

The anti-inflammatory component is documented via the NF-κB and MAPK signalling pathways and the PGE₂ route. A frequently claimed direct inhibition of 5-lipoxygenase by myrcene could not be backed by a primary source and should not be presented as established.

3. Glutamate/GABA balance and endocannabinoids

After a brain injury the balance between excitatory glutamate and inhibitory GABA tips toward over-excitation. A recent study (Bonsale et al. 2025) found in mice that chronic myrcene (200 mg/kg) lowers raised glutamate, raises GABA and glycine, and reduces the endocannabinoids anandamide and 2-AG – alongside normalised behaviour. Notably, myrcene here lowers endocannabinoids rather than raising them – consistent with myrcene not being a direct cannabinoid-receptor agonist.

4. Antioxidant effects

Reviews (Surendran et al. 2021) describe antioxidant properties: in various models myrcene can buffer oxidative stress, restore antioxidant enzymes, and lower lipid peroxidation.

The entourage-effect controversy

The popular claim that myrcene “modulates THC” or “opens the blood-brain barrier” is scientifically contested – and, in its strongest form, unproven.

Against: several independent labs found no direct activity of myrcene at the cannabinoid receptors CB1/CB2 or at TRP channels, and no modulation of THC (Santiago et al. 2019; Finlay et al. 2020; Heblinski et al. 2020). The much-cited Russo (2011) review was a hypothesis, not proof.

For (with caveats): the study often cited as counter-evidence, LaVigne et al. (2021), did not test myrcene (it tested α-humulene, β-pinene, linalool, geraniol). In an oocyte study (Raz et al. 2023) myrcene weakly activated CB1 but, combined with THC, showed no genuine added synergy. In-vivo work (McDougall & McKenna 2022; Alayoubi et al. 2025) points to an indirect involvement of the cannabinoid system in pain relief – without direct receptor binding.

In short: weak signals yes, established THC-boosting by myrcene no.

The dose problem

Almost all described effects appeared at animal doses of roughly 10 to 200 mg per kg body weight. The amounts of myrcene inhaled from cannabis are orders of magnitude lower, and vaping loses further fractions. Solid data on the uptake of inhaled myrcene in humans are largely missing. Extrapolating the animal data to real consumption amounts is therefore not established.

State of research

As of July 2026, all mechanisms named rest on preclinical data (cell culture, mouse, rat). There are no controlled human efficacy studies on isolated myrcene. The evidence may change – this article will be updated when solid new studies appear.

Structure and relationships

Isoprene (C5)
|
+-- Monoterpene (C10H16)
|     |
|     +-- beta-Myrcene [natural isomer]
|     +-- alpha-Myrcene [barely natural]
|
+-- Light + oxygen (photo-oxidation)
      |
      +-- Hashishene [documented hashish marker]

Sources